Transgene and NEC Corporation announced that new data will be presented on TG4050, an individualized neoantigen cancer vaccine, at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida. TG4050 is based on Transgene's myvac(R) platform and powered by NEC's cutting-edge AI capabilities. The new positive data have been generated from patients with HPV-negative head and neck cancer and with ovarian cancer, who have been enrolled in two ongoing Phase I trials assessing TG4050.

TG4050 has demonstrated the ability to induce strong immune responses against targeted antigens in patients, which are expected to result in extended remission periods. An abstract and poster can be accessed on the AACR and Transgene websites. Dr. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology) will discuss the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a live virtual event taking place on April 19, 2023 (12:00 pm ET; 6:00 pm CET).

Click here to register or listen to the replay. About the clinical trials TG4050 is being evaluated in two Phase I clinical trials for patients with HPV-negative head & neck cancers (NCT04183166) and ovarian cancer (NCT03839524). In a first Phase I trial, TG4050 is being administered to patients with HPV-negative headand neck cancer.

An individualized treatment is created for each patient after they complete surgery and while they receive an adjuvant therapy. Half of the participants receive their vaccine immediately after they complete their adjuvant treatment. In France, the clinical trial is being conducted at Institut Curie by Prof. Christophe Le Tourneau, MD, PhD, Head of the Department of Drug Development and Innovation (D3i), and at the IUCT-Oncopole, Toulouse by Prof. Jean-Pierre Delord, MD, PhD.

In the USA, the trial is being led by Yujie Zhao, MD, PhD, at the Mayo Clinic. Endpoints of the trial include safety, feasibility and biological activity of the therapeutic vaccine. In parallel, a Phase I clinical trial of TG4050 is enrolling patients with ovarian cancer.

This second trial is including patients at the time of asymptomatic relapse after surgery and first-line chemotherapy. Matthew Block, MD, PhD, Consultant Medical Oncology, Consultant Immunology and Associate Professor of Oncology at the Mayo Clinic (USA) is the principal investigator of the trial; in France, the trial is being conducted by Prof. Le Tourneau, MD, PhD, at Institut Curie and by Alexandra Martinez, MD, Associate Head of Surgical Department, at IUCT-Oncopole. Endpoints of the trial include safety, feasibility and biological activity of the therapeutic vaccine.

The first preliminary clinical data generated from the first patients treated with TG4050 were very encouraging.